Verastem Reports Second Quarter 2015 Financial and Corporate Results

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering along with creating drugs to always be able to treat cancer by the specific killing associated with cancer stem cells, nowadays reported economic results for your second quarter endedJune 30, 2015, and also provided an please click the up coming article summary of particular corporate accomplishments and plans.

Execution of the continued COMMAND trial will continue to progress well and we remain on track in order to report the outcome with the interim analysis throughout your third quarter of 2015, saidRobert Forre